Chicago Growth Partners I

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

2Checkout is the leading all-in-one monetization platform for global businesses. It was built to help clients drive sales growth across channels and increase market share by simplifying the complexities of modern commerce like global payments, subscription billing, merchandising, taxes, compliance and risk, so they stay focused on innovating their products and delivering exceptional customer experiences.

ScribeAmerica was established in 2003, while the concept of medical scribe utilization in the industry has been anecdotally reported since the 1970's, ScribeAmerica transformed this cottage operation into a national industry. In 2006, we were the first company to demonstrate that the synergy of the Scribe/MD/EMR model could overcome productivity losses experienced by unassisted physicians using EMR. In 2008, we were the first scribe company providing services on both coasts and the only scribe company present at ACEP, AAOS, and SHM. We credit our success to our generous profit-sharing business model whereby the actual Project Leaders who manage our client's programs are rewarded. By enfranchising our employee base, we ensure limited attrition among management and attract the best talent in the industry to run your program.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. The company was founded in 2002 and is based in San Diego, California. It was acquired by [Sanofi Aventis](/organization/sanofi-aventis-2) in 2010.

Compete provides digital intelligence services that help brands improve their marketing based on the online behavior of consumers. The company offers consumer behavior data to research competitors, benchmark performances, identify new and proven keywords, discover referral sources, and find new prospects. It also provides online conversion insights to track online market shares for prospects and customers across top competitors and product categories; discover competitors’ traffic sources; identify opportunities to improve website engagement and conversion metrics based on best practices, direct rivals, and online leaders; measure referral partners; create the offline connection; identify cross-selling and up-selling opportunities; reduce customer care costs; improve customer loyalty; actionable intelligence; and executive-level readouts. In addition, the company offers mobile behavioral intelligence to identify the role of mobile devices in the consumer shopping journey; discover the share of mobile traffi...